Skip to main content

Table 2 Correlations the expression of METTL3, CD33 and clinical parameters in total 197 cervical cancer patients

From: Connecting METTL3 and intratumoural CD33+ MDSCs in predicting clinical outcome in cervical cancer

Clinicopathologic parameter Total case High METTL3 levels in tumor (%) P High METTL3 levels in tumor-infiltrating immune cells (%) P High density of CD33+ MDSCs (%) P
Age
 ≤ 44 (years) 86 31 (43.7%) 0.999a 41 (47.7%) 0.524a 46 (53.5%) 0.672a
 > 44 (years) 111 40 (56.3%)   58 (52.3%)   56 (50.5%)  
 T1 147 59 (40.1%) 0.040a 81 (55.1%) 0.020a 78 (53.1%) 0.536a
 T2–4 50 12 (24.0%)   18 (36.0%)   24 (48.0%)  
N status
 N0 173 64 (37.0%) 0.454a 88 (50.9%) 0.644a 88 (50.9%) 0.493a
 N1 24 7 (29.2%)   11 (45.8%)   14 (58.3%)  
Clinical stage
 I 127 47 (37.0%) 0.703a 68 (53.5%) 0.214a 63 (49.6%) 0.412a
 II–IV 70 24 (34.3%)   31 (44.3%)   39 (55.7%)  
  1. aData are analyzed by Pearson’s chi-squared test
  2. bData are analyzed by Spearman’s chi-squared test